Tower Research Capital (TRC)’s Harvard Bioscience HBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.61K | Buy |
1,152
+912
| +380% | +$5.1K | ﹤0.01% | 4103 |
|
|
2025
Q4 | $1.6K | Sell |
240
-606
| -72% | -$3.6K | ﹤0.01% | 4672 |
|
|
2025
Q3 | $3.71K | Sell |
846
-716
| -46% | -$3.4K | ﹤0.01% | 4461 |
|
|
2025
Q2 | $6.93K | Buy |
1,562
+48
| +3% | +$201 | ﹤0.01% | 4078 |
|
|
2025
Q1 | $8.57K | Buy |
1,514
+972
| +179% | +$12.4K | ﹤0.01% | 3881 |
|
|
2024
Q4 | $11.4K | Buy |
542
+241
| +80% | +$5.54K | ﹤0.01% | 3715 |
|
|
2024
Q3 | $8.08K | Sell |
301
-1,075
| -78% | -$31.7K | ﹤0.01% | 3986 |
|
|
2024
Q2 | $39.2K | Buy |
1,376
+1,339
| +3,619% | +$47K | ﹤0.01% | 3283 |
|
|
2024
Q1 | $1.59K | Sell |
37
-240
| -87% | -$10.8K | ﹤0.01% | 5239 |
|
|
2023
Q4 | $14.8K | Sell |
277
-43
| -13% | -$1.94K | ﹤0.01% | 3856 |
|
|
2023
Q3 | $13.8K | Sell |
320
-928
| -74% | -$42.8K | ﹤0.01% | 3752 |
|
|
2023
Q2 | $68.5K | Buy |
+1,248
| New | +$68.5K | ﹤0.01% | 2319 |
|
|
2022
Q4 | – | Sell |
-376
| Closed | -$9K | – | 6095 |
|
|
2022
Q3 | $9K | Buy |
376
+271
| +258% | +$8.96K | ﹤0.01% | 4656 |
|
|
2022
Q2 | $4K | Sell |
105
-2,824
| -96% | -$127K | ﹤0.01% | 5212 |
|
|
2022
Q1 | $182K | Buy |
2,929
+50
| +2% | +$2.96K | ﹤0.01% | 1803 |
|
|
2021
Q4 | $203K | Buy |
2,879
+2,591
| +900% | +$184K | ﹤0.01% | 1762 |
|
|
2021
Q3 | $20K | Buy |
288
+105
| +57% | +$8.36K | ﹤0.01% | 3705 |
|
|
2021
Q2 | $15K | Sell |
183
-362
| -66% | -$25.6K | ﹤0.01% | 4125 |
|
|
2021
Q1 | $30K | Sell |
545
-456
| -46% | -$22.2K | ﹤0.01% | 3561 |
|
|
2020
Q4 | $43K | Sell |
1,001
-2,671
| -73% | -$99.7K | ﹤0.01% | 3255 |
|
|
2020
Q3 | $110K | Buy |
3,672
+2,931
| +396% | +$98.6K | ﹤0.01% | 3084 |
|
|
2020
Q2 | $23K | Buy |
741
+731
| +7,310% | +$19.7K | ﹤0.01% | 3603 |
|
|
2020
Q1 | $0 | Sell |
10
-108
| -92% | -$2.93K | ﹤0.01% | 3389 |
|
|
2019
Q4 | $3K | Buy |
118
+111
| +1,586% | +$3.19K | ﹤0.01% | 2917 |
|
|
2019
Q3 | $0 | Sell |
7
-1,368
| -99% | -$34K | ﹤0.01% | 4259 |
|
|
2019
Q2 | $28K | Buy |
1,375
+1,101
| +402% | +$32.3K | ﹤0.01% | 1943 |
|
|
2019
Q1 | $12K | Sell |
274
-258
| -48% | -$9.35K | ﹤0.01% | 2572 |
|
|
2018
Q4 | $17K | Sell |
532
-17
| -3% | -$670 | ﹤0.01% | 2055 |
|
|
2018
Q3 | $29K | Buy |
+549
| New | +$30.8K | ﹤0.01% | 2095 |
|
|
2018
Q2 | – | Sell |
-513
| Closed | -$26K | – | 3822 |
|
|
2018
Q1 | $26K | Buy |
+513
| New | +$23K | ﹤0.01% | 2034 |
|
|
2017
Q1 | – | Sell |
-410
| Closed | -$13K | – | 3397 |
|
|
2016
Q4 | $13K | Sell |
410
-42
| -9% | -$1.07K | ﹤0.01% | 2471 |
|
|
2016
Q3 | $12K | Sell |
452
-438
| -49% | -$12.2K | ﹤0.01% | 1933 |
|
|
2016
Q2 | $25K | Buy |
+890
| New | +$28.3K | ﹤0.01% | 2058 |
|
|
2016
Q1 | – | Sell |
-285
| Closed | -$10K | – | 4453 |
|
|
2015
Q4 | $10K | Sell |
285
-171
| -38% | -$5.85K | ﹤0.01% | 2114 |
|
|
2015
Q3 | $17K | Buy |
+456
| New | +$21.2K | ﹤0.01% | 1877 |
|
|
2014
Q4 | – | Sell |
-29
| Closed | -$1K | – | 4277 |
|
|
2014
Q3 | $1K | Buy |
+29
| New | +$1.33K | ﹤0.01% | 4091 |
|
|
2014
Q1 | – | Sell |
-82
| Closed | -$4K | – | 4634 |
|
|
2013
Q4 | $4K | Buy |
82
+65
| +382% | +$2.84K | ﹤0.01% | 3672 |
|
|
2013
Q3 | $1K | Buy |
+17
| New | +$669 | ﹤0.01% | 4302 |
|
Other funds holding HBIO
WCM
VCM
CCM
MIM
NCNMGF
Tower Research Capital (TRC)'s HBIO Position: Q1 2026 in Review
Tower Research Capital (TRC) increased its Harvard Bioscience (HBIO) stake by 380% in Q1 2026, buying an estimated $5.1K and bringing the position to 1,152 shares worth $5.61K. The position accounts for ﹤0.01% of the portfolio, ranked #4103.
Tower Research Capital (TRC) first reported a position in HBIO in Q3 2013 and has held it in 38 quarters since. The position peaked at $203K in Q4 2021. 36 funds tracked by Wall St. Rank hold HBIO as of Q1 2026.
- Tower Research Capital (TRC) held 1,152 shares of Harvard Bioscience worth $5.61K as of Q1 2026.
- Tower Research Capital (TRC) bought 912 Harvard Bioscience shares in Q1 2026, an estimated $5.1K.
- Harvard Bioscience made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4103 holding.
- Tower Research Capital (TRC) first reported a position in Harvard Bioscience in Q3 2013 and has held it in 38 quarters since.
- Tower Research Capital (TRC)'s Harvard Bioscience position peaked at $203K in Q4 2021.
- 36 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.